Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 473,657 shares, an increase of 7,658.5% from the June 30th total of 6,105 shares. Based on an average daily volume of 2,079,462 shares, the days-to-cover ratio is currently 0.2 days. Approximately 7.8% of the company’s stock are sold short.
Institutional Trading of Matinas Biopharma
A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC bought a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent reporting period. 11.77% of the stock is currently owned by institutional investors.
Matinas Biopharma Price Performance
Shares of MTNB stock traded down $0.01 on Friday, hitting $0.24. The company’s stock had a trading volume of 21,013,035 shares, compared to its average volume of 393,812. The stock has a market capitalization of $1.55 million, a price-to-earnings ratio of -0.12 and a beta of 1.71. Matinas Biopharma has a fifty-two week low of $0.23 and a fifty-two week high of $3.09. The firm’s fifty day moving average price is $0.63 and its 200-day moving average price is $0.62.
Matinas Biopharma Company Profile
Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.
The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.
See Also
- Five stocks we like better than Matinas Biopharma
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
